Neervannan Seshadri's Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 21, 2023
- Accession no.
- 0001827584-23-000002
- Filed
- Mar 21, 2023
- Trade date
- Mar 17-20, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $9.57K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Neervannan SeshadriCIK 0001827584 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2023 | Common Stock | SSaleDisposed | −360 | $13.28 | −$4,780.8 | 56,217 | Direct | |
| Mar 20, 2023 | Common Stock | SSaleDisposed | −380 | $12.61 | −$4,791.8 | 55,837 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.